MRPL28 Recombinant Monoclonal Antibody

MRPL28, also known as mitochondrial ribosomal protein L28, serves as an essential component of the 39S large subunit of the mitochondrial ribosome. This protein plays a fundamental role in mitochondrial protein synthesis, which is critical for oxidative phosphorylation and cellular energy production. Notably, MRPL28 has also been identified as a melanoma-associated antigen recognized by cytotoxic T-lymphocytes, making it relevant to cancer immunology research and studies exploring tumor-immune interactions.

This recombinant monoclonal antibody, generated from clone 14B4 in rabbit host, offers the reproducibility and consistency that demanding experimental workflows require. Because recombinant antibodies are produced from defined sequences rather than traditional hybridoma methods, researchers benefit from lot-to-lot uniformity that supports longitudinal studies and ensures reliable results across experiments.

The antibody has been validated for Western blotting, flow cytometry, and ELISA applications, providing flexibility across multiple experimental platforms. Western blot analysis demonstrates robust detection across a broad panel of human cell lines including HepG2, COLO205, HEK293T, HeLa, Jurkat, and MCF7, with an observed band at the predicted molecular weight of 49 kDa. Cross-species reactivity has been confirmed through successful detection in mouse and rat kidney tissue lysates, expanding utility for researchers working with rodent models. Flow cytometry validation in HeLa cells shows clear separation between antibody-stained and control populations, confirming suitability for intracellular protein detection in fixed and permeabilized cells.

This antibody supports investigations into mitochondrial biology, cellular metabolism, and cancer immunology, offering researchers a dependable tool for exploring MRPL28 function across diverse experimental contexts.